COVID-19 therapies for inpatients: a review and quality assessment of clinical guidelines. Issue 4 (21st November 2022)

• Record Type: Journal Article
• Authors: Wohl, David A.; Espinueva, Aprille A.; Dau, Lauren; Wang, Chen-Yu; Lachmann, Alexandra; Bam, Rujuta A.; Rawal, Aaditya; Chappell-Smith, Kerris; Rockstroh, Juergen K.
• Is Part Of: ERJ open research. Volume 8:Issue 4(2022)
• Publication Date: 2022-11-21
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; Respiration; Respiratory organs -- Diseases; Respiratory organs -- Diseases -- Treatment; Respiratory Tract Diseases; Electronic journals; Fulltext; Internet Resources; Periodicals; Periodical; 616.2005
• DOI: 10.1183/23120541.00236-2022
• Languages: English
• ISSNs: 2312-0541

Abstract

Owing to condensed development processes, expanding evidence and differences in healthcare system characteristics, many COVID-19 guidelines differ in their quality and treatment recommendations, which has consequences for clinical practice. This review aimed to identify COVID-19 treatment guidelines, assess their quality and summarise their recommendations. Guidelines were identified for five therapies most commonly used among inpatients with COVID-19 (remdesivir, dexamethasone, tocilizumab, baricitinib and casirivimab/imdevimab) from 11 countries. Guideline quality was assessed using the Appraisal of Guidelines for Research and Evaluation II (AGREE-II) tool. Full details of recommendations and supporting evidence were analysed for high-quality guidelines, defined as those scoring ≥50% in Domain 3 (Rigour of Development) of AGREE-II. Overall, guidelines differed substantially in their quality and, even among high-quality guidelines using the same evidence, recommendations regarding specific therapeutics varied. Potential reasons for this heterogeneity, including the availability and consistency of clinical data, visibility of trial end-points and context-specific factors, are discussed. This targeted review of #COVID19 treatment guidelines aimed to understand the heterogeneity in quality, recommendations and evidence bases for therapies commonly used among COVID-19 inpatients https://bit.ly/3T34G7Y